| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -5.9 | -1.5 |
| EPS (diluted, $ a share) | $-7.33 | $-1.83 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: RTSN. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Retension Pharmaceuticals, Inc.: key numbers
- Share price
- $11.46Close, Nov 16
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Retension Pharmaceuticals, Inc.
All →Retension Pharmaceuticals Financial Results
Retension Pharmaceuticals reported Q3 2026 financial results and provided a corporate update following its $51.75 million upsized IPO in October 2026. The company is currently conducting a Phase 2b clinical trial for its hypertension candidate RTN-001, with topline data expected in the first half of 2027.
- Term
- Q3 2026
“Completing our initial public offering was an important step for Retension, and it provides the capital to complete our Phase 2b clinical trial of RTN-001 and prepare for Phase 3.”
Eric Keller, Chief Executive Officer of Retension Pharmaceuticals
Retension Pharmaceuticals Executive Compensation
Retension Pharmaceuticals appointed Robert Wong as Vice President and Chief Accounting Officer, effective November 2, 2026. His compensation package includes an annual base salary of $360,000, a 30% target bonus opportunity, a $20,000 sign-on bonus, and a stock option award for 25,000 shares.
- Counterparty
- Robert Wong
Retension Pharmaceuticals CEO Eric L. Keller Buys $250K of Stock
Eric L. Keller, CEO, bought 20,800 shares of Retension Pharmaceuticals, Inc. at $12.00 a share, worth $250K in total on Oct 13, 2026. Shares held after the trade: 423,377 (+5.2%).
- Value
- $250K
- Shares
- 20,800
- Price
- $12.00
- Role
- CEO
- Holding change
- +5.2%
- Trade date
- Oct 13, 2026
Retension Pharmaceuticals Insider Franklin M. Berger Buys $120K of Stock
Franklin M. Berger bought 10,000 shares of Retension Pharmaceuticals, Inc. at $12.00 a share, worth $120K in total on Oct 13, 2026. Shares held after the trade: 10,000.
- Value
- $120K
- Shares
- 10,000
- Price
- $12.00
- Trade date
- Oct 13, 2026